✦ LIBER ✦

High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer

✍ Scribed by George Somlo; James H. Doroshow; Stephen J. Forman; Lucille A. Leong; Kim A. Margolin; Robert J. Morgan Jr.; James W. Raschko; Steven A. Akman; Chul Ahn; Stuart Nagasawa; Jonathan Harrison; The City of Hope Bone Marrow Oncology Team

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 780 KB
Volume: 73
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19940315)73:6<1678::aid-cncr2820730621>3.0.co;2-u

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose cisplatin, etoposide, and cycl

High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer

✍ George Somlo; James H. Doroshow; Stephen J. Forman; Lucille A. Leong; Kim A. Mar 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 901 KB

High-dose mitoxantrone and cyclophospham

High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma : A Phase II multicentric trial

✍ Jose Luis Pérez-Gracia; Ramon Colomer; Emilio Esteban; Ramón Barceló; Manuel Ben 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

P53 is the strongest predictor of surviv

P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support

✍ Manfred Hensel; Andreas Schneeweiss; Hans-Peter Sinn; Gerlinde Egerer; Erich Sol 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 129 KB 👁 3 views

## Abstract Our purpose was to determine the predictive value of tumor biologic parameters in patients with HRPBC who received HDCT with ASCT as first‐line treatment. From September 1992 to May 2000, 149 stage II or III HRPBC patients were enrolled in a single‐arm trial using a tandem HDCT regimen

Predictors for pneumonitis during locore

Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue

✍ Pehr A. Lind; Lawrence B. Marks; Timothy A. Jamieson; Dennis L. Carter; James J. 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 1 views

## Abstract ## BACKGROUND To study the predictive value of serial pulmonary function testing (PFT) for toxicity in patients who have received high‐dose chemotherapy (HDCT) and stem‐cell rescue for breast carcinoma. These patients are at risk of developing therapy‐related pneumonitis (TRP) during o

High histologic and overall response to

High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk ewing sarcoma family tumors : The Bambino Gesù Children's Hospital experience

✍ Giuseppe Maria Milano; Raffaele Cozza; Ilaria Ilari; Luigi De Sio; Renata Boldri 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame